lutetium-177 + FAP-2286

**Lutetium-177 + FAP-2286** is a peptide-targeted radiopharmaceutical therapy (PTRT) that combines the radionuclide lutetium-177 with the FAP-2286 peptide, which selectively binds to fibroblast activation protein (FAP). FAP is expressed on cancer-associated fibroblasts within the tumor microenvironment in a wide range of epithelial cancers, as well as some tumors of mesenchymal origin. After binding to FAP, the lutetium-177 emits beta radiation and gamma rays, delivering targeted cytotoxic radiation to FAP-expressing cells while enabling imaging. The drug is administered intravenously and is under clinical investigation primarily for advanced solid tumors such as non-small cell lung cancer, pancreatic ductal adenocarcinoma, and breast cancer, both as monotherapy and in combination with chemotherapy. Early clinical data suggest efficacy and a favorable safety profile in these populations[1][2][3].